ArticleAlzheimer's & dementia (New York, N. Y.)2021
Building clinically relevant outcomes across the Alzheimer's disease spectrum.
Article in Alzheimer's & dementia (New York, N. Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of the safety and efficacy on cognitive function of herbal and nutritional medicines in older adults with and without subjective cognitive impairment.Systematic reviews · 2023Pooled it
- Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study.The journal of prevention of Alzheimer's disease · 2024Trial
- Speech and language outcome measures in clinical trials of Alzheimer's and Parkinson's diseases.Expert review of neurotherapeutics · 2026Review
- Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity.JAMA · 2025Observational
- Smartphone- and Tablet-Based Tools to Assess Cognition in Individuals With Preclinical Alzheimer Disease and Mild Cognitive Impairment: Scoping Review.Journal of medical Internet research · 2025Article
- Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer's disease compared to comorbid cases; proof of concept in the ADNI study.Molecular psychiatry · 2025Article
- Treatment of Acute and Long-COVID, Diabetes, Myocardial Infarction, and Alzheimer's Disease: The Potential Role of a Novel Nano-Compound-The Transdermal Glutathione-Cyclodextrin Complex.Antioxidants (Basel, Switzerland) · 2024Review
- Care partner-informed meaningful change thresholds for the Clinical Dementia Rating-Sum of Boxes for trials of early Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- How donanemab data address the coverage with evidence development questions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
- Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's disease.Alzheimer's research & therapy · 2024Article
- Clinical importance in Alzheimer's disease: effects of anchor agreement and disease severity.Aging clinical and experimental research · 2024Article
- Observational studies of treatment effectiveness in neurology.Brain : a journal of neurology · 2023Review
- Accelerating Alzheimer's therapeutic development: The past and future of clinical trials.Cell · 2023Review
- Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease.Neurology and therapy · 2023Article
- Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Determining the Minimal Important Change of Everyday Functioning in Dementia: Pursuing Clinical Meaningfulness.Neurology · 2022Article
- Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease.The journal of prevention of Alzheimer's disease · 2022Review
- Building clinically relevant outcomes across the Alzheimer's disease spectrum.Alzheimer's & dementia (New York, N. Y.) · 2021Article
- Open peer review commentary on building clinically relevant outcomes across the Alzheimer's disease spectrum.Alzheimer's & dementia (New York, N. Y.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Demonstrating that treatments are clinically meaningful across the Alzheimer's disease (AD) continuum is critical for meeting our goals of accelerating a cure by 2025. While this topic has been a focus of several Alzheimer's Association Research Roundtable (AARR) meetings, there remains no consensus as to what constitutes a "clinically meaningful outcome" in the eyes of patients, clinicians, care partners, policymakers, payers, and regulatory bodies. Furthermore, the field has not come to agreement as to what constitutes a clinically meaningful treatment effect at each stage of disease severity. The AARR meeting on November 19-20, 2019, reviewed current approaches to defining clinical meaningfulness from various perspectives including those of patients and care partners, clinicians, regulators, health economists, and public policymakers. Participants discussed approaches that may confer clinical relevance at each stage of the disease continuum and fostered discussion about what should guide us in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.